Attention & Memory Impairments in Menopausal Women

Completed · Phase 4 · Has a placebo group

Conditions studied: Symptomatic Menopause, Cognitive Impairments

In brief

The purpose of this study is to determine whether a medication called Vyvanse® (lisdexamfetamine; LDX) has an impact on cognitive functioning, specifically measures of sustained attention, verbal encoding and recall and working memory, in menopausal aged women. LDX is a medication used to treat attention deficit hyperactivity disorder (ADHD). The cognitive difficulties that menopausal women report experiencing are typical of adults who are diagnosed with ADHD. The investigators will assess whether or not LDX is effective in alleviating those cognitive disruptions when compared to a placebo.

Key facts

Study ID
NCT01324024
Run by
University of Pennsylvania
People needed
35
Starts
2011-05-01
Expected to finish
2014-04-01
Last updated by the study team
2017-06-28

Who can join

Age: 45 and older, up to 60. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.